42 results on '"Claus, Christina"'
Search Results
2. Combining mathematical modeling, in vitro data and clinical target expression to support bispecific antibody binding affinity selection: a case example with FAP-4-1BBL.
3. A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology
4. NAB1 Is an RNA Binding Protein Involved in the Light-Regulated Differential Expression of the Light-Harvesting Antenna of Chlamydomonas reinhardtii
5. P1211: TUMOR-ACTIVATED LYMPH NODE FIBROBLASTS SUPPRESS T CELL FUNCTION IN DIFFUSE LARGE B CELL LYMPHOMA
6. CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies
7. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
8. Abstract 1100: 4-1BBL agonist targeted to fibroblast activation protein α synergizes with radiotherapy in murine breast tumor
9. Supplementary Data from The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
10. Data from The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
11. Figure S2 from The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
12. Supplementary Figures 1-3 from CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
13. Data from CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
14. A model‐based approach leveraging in vitro data to support dose selection from the outset : A framework for bispecific antibodies in immuno‐oncology
15. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
16. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
17. RG6333 (CD19-CD28), a CD19-Targeted Affinity-Optimized CD28 Bispecific Antibody, Enhances and Prolongs the Anti-Tumor Activity of Glofitamab (CD20-TCB) in Preclinical Models
18. Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist
19. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells
20. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity
21. Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer
22. RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies
23. 370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors
24. Abstract LB-389: Combination of TYRP1-TCB, a novel T cell bispecific antibody for the treatment of melanoma, with immunomodulatory agents
25. Abstract 6135: Tumor-bearing non-human primates: An unrivaled model for translational cancer immunology research
26. Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer
27. The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
28. Abstract 1129: Monitoring intratumoral CD8 T cell infiltrates in human stem cell engrafted mice during single agent and combination immunotherapy with T cell bispecific antibodies using the human PET-tracer89Zr-Df-IAB22M2C
29. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
30. Abstract 957: Design of CD19-4-1BBL, a novel CD19-targeted 4-1BB ligand for combination therapy with CD20 T-cell bispecific antibodies and CD20 antibodies
31. Abstract 5621: FAP-4-1BBL: A novel versatile tumor-stroma targeted 4-1BB agonist for combination immunotherapy with checkpoint inhibitors, T-cell bispecific antibodies, and ADCC-mediating antibodies
32. CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
33. Destruction of Lymphoid Organ Architecture and Hepatitis Caused by CD4+ T Cells
34. Chronic myelogenous leukemia maintains specific CD8+ T cells through IL‐7 signaling
35. CD4+T cell help improves CD8+T cell memory by retained CD27 expression
36. Destruction of Lymphoid Organ Architecture and Hepatitis Caused by CD4+ T Cells.
37. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.
38. CD4.
39. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
40. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells
41. The PET-Tracer 89 Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment.
42. CD4+ T cell help improves CD8+ T cell memory by retained CD27 expression.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.